Anaissie 1996.

Study characteristics
Methods	Not placebo‐controlled, not blinded, industry‐sponsored, single‐center trial
Participants	Adults; mixed tumors; ANC < 1 x 109/L
Interventions	GM‐CSF (Sandoz) 3 mcg/kg IV ATB: Ticarcilin plus Netilmicin
Outcomes	Overall mortality Infection‐related mortality People with hospitalization for greater than 10 days
Notes	Hospital discharge criteria: Not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated sequence of numbers was used
Allocation concealment (selection bias)	Unclear risk	We were not able to assess the adequacy of allocation concealment based on the information provided in the article
Blinding (performance bias and detection bias) All outcomes	High risk	There was no blinding
Blinding of participants and personnel (performance bias) All outcomes	High risk	There was no blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	There was no blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis used, Withdrawals are described
Other bias	High risk	Prespecified values of sample size, alpha and beta errors were not provided